Fifth and final bid? A determined Takeda said to be nearing $60B-plus Shire deal

Takeda US facility
Takeda and Shire could announce a preliminary deal agreement as soon as Tuesday, Bloomberg's sources say. (Takeda)

Takeda may just go unchallenged after all in its quest to swallow Shire.

With a fifth offer from the Japanese drugmaker on the table, the companies are nearing a tie-up pact, sources told Bloomberg, and they may have a preliminary agreement to announce as soon as Tuesday. Such a move would come just one day before Takeda’s deadline to put forth a firm offer or walk away under U.K. takeover rules.

Shire said Friday it was considering Takeda’s fourth bid—a £47 billion offer ($61.6 billion) comprising £26 per share in new Takeda shares and £21 per share in cash—after shooting down three previous offers. And Tuesday morning, the Dublin drugmaker said its suitor had sweetened the deal even more, though it didn’t reveal the offer’s terms. A cash component bump-up may be part of the new proposal, if recent analyst speculation proves correct.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

While there’s been plenty of talk about a Big Pharma competitor stepping in with its own Shire bid, so far none have come forward. Late last week, Allergan confirmed that it was talking with the rare-disease specialist, though it formally withdrew from the takeover process just a few short hours later.

RELATED: With big debt on tap, analysts see Takeda-Shire deal as 'more likely than not'

Still, industry watchers have seen Takeda as somewhat of an underdog thanks to its smaller size. To nab Shire, it would have to go into some serious debt, although that’s a possibility the company has said it's ready for.

On the other hand, if Takeda does buy Shire, it’ll join the ranks of the world’s largest drugmakers. Shire will bolster its GI and neuroscience units and give it an entry into rare diseases and hemophilia.


Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.